Literature DB >> 27149047

Vital Signs: National and State-Specific Patterns of Attention Deficit/Hyperactivity Disorder Treatment Among Insured Children Aged 2-5 Years - United States, 2008-2014.

Susanna N Visser, Melissa L Danielson, Mark L Wolraich, Michael H Fox, Scott D Grosse, Linda A Valle, Joseph R Holbrook, Angelika H Claussen, Georgina Peacock.   

Abstract

BACKGROUND: Attention deficit/hyperactivity disorder (ADHD) is associated with adverse outcomes and elevated societal costs. The American Academy of Pediatrics (AAP) 2011 guidelines recommend "behavior therapy" over medication as first-line treatment for children aged 4-5 years with ADHD; these recommendations are consistent with current guidelines from the American Academy of Child and Adolescent Psychiatry for younger children. CDC analyzed claims data to assess national and state-level ADHD treatment patterns among young children.
METHODS: CDC compared Medicaid and employer-sponsored insurance (ESI) claims for "psychological services" (the procedure code category that includes behavior therapy) and ADHD medication among children aged 2-5 years receiving clinical care for ADHD, using the MarketScan commercial database (2008-2014) and Medicaid (2008-2011) data. Among children with ESI, ADHD indicators were compared during periods preceding and following the 2011 AAP guidelines.
RESULTS: In both Medicaid and ESI populations, the percentage of children aged 2-5 years receiving clinical care for ADHD increased over time; however, during 2008-2011, the percentage of Medicaid beneficiaries receiving clinical care was double that of ESI beneficiaries. Although state percentages varied, overall nationally no more than 55% of children with ADHD received psychological services annually, regardless of insurance type, whereas approximately three fourths received medication. Among children with ESI, the percentage receiving psychological services following release of the guidelines decreased significantly by 5%, from 44% in 2011 to 42% in 2014; the change in medication treatment rates (77% in 2011 compared with 76% in 2014) was not significant. CONCLUSIONS AND COMMENTS: Among insured children aged 2-5 years receiving clinical care for ADHD, medication treatment was more common than receipt of recommended first-line treatment with psychological services. Among children with ADHD who had ESI, receipt of psychological services did not increase after release of the 2011 guidelines. Scaling up evidence-based behavior therapy might lead to increased delivery of effective ADHD management without the side effects of ADHD medications.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27149047     DOI: 10.15585/mmwr.mm6517e1

Source DB:  PubMed          Journal:  MMWR Morb Mortal Wkly Rep        ISSN: 0149-2195            Impact factor:   17.586


  26 in total

1.  Legal Epidemiology: The Science of Law.

Authors:  Tara Ramanathan; Rachel Hulkower; Joseph Holbrook; Matthew Penn
Journal:  J Law Med Ethics       Date:  2017-03       Impact factor: 1.718

2.  A National Description of Treatment among United States Children and Adolescents with Attention-Deficit/Hyperactivity Disorder.

Authors:  Melissa L Danielson; Susanna N Visser; Andrea Chronis-Tuscano; George J DuPaul
Journal:  J Pediatr       Date:  2017-11-10       Impact factor: 4.406

3.  Prevalence of Parent-Reported ADHD Diagnosis and Associated Treatment Among U.S. Children and Adolescents, 2016.

Authors:  Melissa L Danielson; Rebecca H Bitsko; Reem M Ghandour; Joseph R Holbrook; Michael D Kogan; Stephen J Blumberg
Journal:  J Clin Child Adolesc Psychol       Date:  2018-01-24

4.  Interpreting the Prevalence of Mental Disorders in Children: Tribulation and Triangulation.

Authors:  Joseph R Holbrook; Rebecca H Bitsko; Melissa L Danielson; Susanna N Visser
Journal:  Health Promot Pract       Date:  2016-11-16

5.  Off-label Prescribing Trends for ADHD Medications in Very Young Children.

Authors:  Shannon G Panther; Alice M Knotts; Tamara Odom-Maryon; Kenneth Daratha; Teri Woo; Tracy A Klein
Journal:  J Pediatr Pharmacol Ther       Date:  2017 Nov-Dec

6.  Treated Prevalence of Attention-Deficit/Hyperactivity Disorder Increased from 2009 to 2015 Among School-Aged Children and Adolescents in the United States.

Authors:  Kwame A Nyarko; Scott D Grosse; Melissa L Danielson; Joseph R Holbrook; Susanna N Visser; Stuart K Shapira
Journal:  J Child Adolesc Psychopharmacol       Date:  2017-03-22       Impact factor: 2.576

7.  A National Profile of Attention-Deficit Hyperactivity Disorder Diagnosis and Treatment Among US Children Aged 2 to 5 Years.

Authors:  Melissa L Danielson; Susanna N Visser; Mary Margaret Gleason; Georgina Peacock; Angelika H Claussen; Stephen J Blumberg
Journal:  J Dev Behav Pediatr       Date:  2017-09       Impact factor: 2.225

8.  Preschool ADHD Diagnosis and Stimulant Use Before and After the 2011 AAP Practice Guideline.

Authors:  Alexander G Fiks; Michelle E Ross; Stephanie L Mayne; Lihai Song; Weiwei Liu; Jennifer Steffes; Banita McCarn; Robert W Grundmeier; A Russell Localio; Richard Wasserman
Journal:  Pediatrics       Date:  2016-11-15       Impact factor: 7.124

9.  Medicaid Prior Authorization Policies for Medication Treatment of Attention-Deficit/Hyperactivity Disorder in Young Children, United States, 2015.

Authors:  Rachel L Hulkower; Meghan Kelley; Lindsay K Cloud; Susanna N Visser
Journal:  Public Health Rep       Date:  2017-10-26       Impact factor: 2.792

10.  Adherence to Recommended Care Guidelines in the Treatment of Preschool-Age Medicaid-Enrolled Children With a Diagnosis of ADHD.

Authors:  Alex Moran; Nicoleta Serban; Melissa L Danielson; Scott D Grosse; Steven P Cuffe
Journal:  Psychiatr Serv       Date:  2018-10-30       Impact factor: 3.084

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.